LMN-201 for Prevention of C. Difficile Infection Recurrence | MicrobiomeTrials← Back to trialsNCT05330182
LMN-201 for Prevention of C. Difficile Infection Recurrence
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2024-08-29Est. Completion: 2027-06-01
Enrollment target: 375 participants Locations- Kaiser Permanente, Escondido, California, United States
- Bridgeport Hospital, Bridgeport, Connecticut, United States
- Gastroenterology Center of Connecticut, Hamden, Connecticut, United States
- GI PROS Research, Naples, Florida, United States
- Metro Infectious Disease Consultants - Atlanta, Decatur, Georgia, United States
- Snake River Research, Idaho Falls, Idaho, United States
- Metro Infectious Disease Consultants, LLC, Burr Ridge, Illinois, United States
- DM Clinical Research, Oak Lawn, Illinois, United States
- Baptist Health Research, Lexington, Kentucky, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Mercury Street Medical, Butte, Montana, United States
- Quality Clinical Research, Inc, Omaha, Nebraska, United States
- Weill Cornell Medicine, New York, New York, United States
- IMA Clinical Research, Mount Airy, North Carolina, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC, Annandale, Virginia, United States
Other microbiome trials you might be interested in
Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection RecurrenceClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceCDIC. Diff InfectionRecurrent Clostridium Difficile InfectionC.Difficile DiarrheaDiarrhea Infectious
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (…
Huntsville, United StatesEst. completion Jun 2027
The gut microbiota plays a crucial role in human health, influencing metabolism, immunity, and pathogen resistance. Rese…
Rome, ItalyEst. completion Mar 10, 2027
Clostridium Difficile Infection
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …
Multiple LocationsEst. completion Aug 22, 2028